Evvy, a pioneering women’s health company at the forefront of vaginal microbiome research, has successfully closed a $40 million Series B funding round, spearheaded by Catalio Capital Management. This significant capital injection is poised to accelerate Evvy’s mission to revolutionize women’s healthcare through advanced diagnostics, personalized treatment, and a robust data infrastructure designed to bridge critical gaps in medical understanding. The announcement underscores growing investor confidence in the burgeoning femtech sector and the urgent need for more tailored, evidence-based approaches to women’s health.
Pioneering the Vaginal Microbiome: A New Era of Diagnostics
Since its inception in 2021, Evvy has distinguished itself by operating what it touts as the world’s only at-home CLIA-certified and CLEP-certified metagenomic sequencing (mNGS) test for analyzing vaginal microbes. This innovative diagnostic tool allows individuals to collect a swab sample from the comfort of their homes, which is then mailed to Evvy’s specialized laboratory for comprehensive analysis. The certifications, CLIA (Clinical Laboratory Improvement Amendments) and CLEP (Clinical Laboratory Evaluation Program), are crucial, signifying that Evvy’s lab adheres to stringent federal and state standards for quality, accuracy, and reliability in diagnostic testing, assuring both patients and clinicians of the integrity of the results.
The core of Evvy’s technology lies in its use of metagenomic sequencing. Unlike traditional culture-based tests or even 16S rRNA gene sequencing, mNGS offers an unparalleled depth of insight into the entire genetic material present in a sample. This allows for the identification of all microbes—bacteria, fungi, viruses—present in the vaginal microbiome, including those that are difficult or impossible to culture in a lab, and even novel, previously uncatalogued species. This comprehensive approach is vital because the vaginal microbiome is a complex ecosystem whose delicate balance profoundly impacts a woman’s health, influencing everything from susceptibility to infections like bacterial vaginosis (BV) and yeast infections to reproductive outcomes and even cancer risk.
Upon receiving the swab samples, Evvy’s lab employs its proprietary mNGS sequencing protocols. The raw genetic data is then processed and analyzed, with results subsequently sent to clinicians registered on Evvy’s platform for thorough review. This two-tiered approach ensures clinical oversight and professional interpretation. Patients gain access to their results through a secure online health portal, where the data is presented alongside a clear diagnosis, a clinical interpretation that translates complex scientific findings into understandable insights, and a personalized path of next steps. This often includes tailored prescription care when deemed relevant by a clinician, ensuring that diagnostic findings translate directly into actionable health solutions.
Priyanka Jain, CEO and co-founder of Evvy, emphasized the clarity and utility of the patient experience. "When a patient receives their results, they are presented alongside a diagnosis, clinical interpretation, and a clear path of next steps, including personalized prescription care when relevant," Jain stated, highlighting the company’s commitment to empowering patients with actionable information rather than just raw data. This integrated approach addresses a significant pain point in healthcare where patients often receive test results without adequate explanation or guidance on what to do next.
Rapid Growth and Scientific Contributions: A Timeline of Impact
Since its public launch in July 2021, supported by an initial $5 million seed round led by General Catalyst, Evvy has demonstrated remarkable growth and made substantial contributions to the field of women’s health. The company now serves a broad base of over 100,000 patients across the United States, a testament to the unmet need for advanced vaginal health diagnostics. Concurrently, Evvy has cultivated a robust network of 3,000 practitioners who integrate its testing and insights into their clinical practices, expanding the reach and impact of its data-driven approach.
Beyond patient care, Evvy has emerged as a significant contributor to scientific research. The company has generated 15 peer-reviewed publications and abstracts, actively advancing the collective understanding of the vaginal microbiome. These research efforts have led to critical discoveries, including the identification of novel subtypes of bacterial vaginosis—a common and often recurrent condition that impacts millions of women annually and is frequently misdiagnosed or inadequately treated. Furthermore, Evvy’s extensive sequencing efforts have uncovered hundreds of previously uncatalogued vaginal microbiome genomes, enriching global genomic databases and providing foundational data for future research into microbial diversity and its implications for human health.
Jain noted that this wealth of collected data empowers clinicians to offer truly personalized treatment strategies. The ability to precisely identify the microbial composition of a patient’s vaginal environment allows for targeted interventions, moving beyond broad-spectrum antibiotics that can disrupt beneficial bacteria and contribute to resistance. This precision medicine approach is crucial for chronic and recurrent conditions that have historically frustrated both patients and providers.
A Data-Driven Revolution: Bridging the Gender Data Gap
Evvy’s ambition extends far beyond individual diagnostics; its bigger goal is to construct an expansive dataset that intricately links microbiome biology, patient symptoms, medical interventions, and health outcomes. This initiative aims to create a "continuous feedback loop that unlocks improvements to care and the discovery of entirely new biomarkers," as articulated by Jain. Such a comprehensive dataset has the potential to transform our understanding of women’s health conditions, identifying patterns and correlations that are currently obscured by fragmented data.
At the heart of Evvy’s strategic vision is the critical recognition of a fundamental flaw in the current landscape of precision medicine: the profound lack of high-quality, representative data on female bodies. Historically, medical research and clinical trials have predominantly focused on male physiology, often extrapolating findings to women without adequate validation. This long-standing bias has created a significant "gender data gap," leading to diagnostic delays, suboptimal treatments, and a general lack of understanding of conditions that disproportionately affect women or manifest differently in female physiology. For instance, conditions like endometriosis often take an average of 7-10 years for diagnosis due to a lack of awareness, research, and objective biomarkers.
"You can’t build precision medicine for women on datasets that never adequately measured female biology in the first place," Jain asserted, drawing attention to how even leading AI models often struggle to accurately answer questions pertinent to women’s health, a direct consequence of this data disparity. This highlights the urgent need for dedicated, large-scale data collection efforts focused on female biology.
Jain firmly believes that AI, when coupled with new biological data at scale, holds the key to unlocking unprecedented insights. "AI can help us identify patterns across molecular signals, hormones, symptoms, treatments, fertility outcomes, and other biomarkers that traditional medicine has struggled to connect," she explained. By feeding vast amounts of high-quality, female-specific biological data into advanced AI algorithms, Evvy aims to uncover complex relationships and predictive markers that could revolutionize diagnostic and therapeutic pathways.
EvvyAI: Intelligent Guidance for Vaginal Health
In May, Evvy further cemented its commitment to leveraging technology by launching EvvyAI, an AI assistant designed to serve as an advisor for vaginal health. This innovative tool translates the rich microbiome data collected by Evvy into real-time, personalized guidance for users. EvvyAI is not intended to replace clinicians but rather to empower patients with immediate, accessible information, helping them understand their results and potential implications. Crucially, for questions requiring expert medical opinions or a deeper clinical consultation, EvvyAI responsibly directs patients to qualified clinicians, ensuring that complex health decisions remain within the purview of healthcare professionals. This exemplifies a thoughtful integration of AI into healthcare, enhancing patient understanding while maintaining the essential role of human expertise.
Expanding Horizons: Fertility and Beyond
From its inception, Evvy’s co-founders were driven by the conviction that indicators within the vaginal biome could be leveraged to "predict and improve outcomes across the female lifespan." This expansive vision is now materializing as the startup makes its first major foray beyond general vaginal health into the critical and often challenging domain of fertility.
The company is actively compiling extensive data and conducting scientific research specifically linking vaginal microbiomes to various aspects of reproductive health. This includes investigating connections to infertility, gynecological cancers, preterm birth, the success rates of in vitro fertilization (IVF), and recurrent pregnancy loss. These areas represent some of the most emotionally and physically taxing challenges women face, and a deeper understanding of the microbiome’s role could offer new avenues for prevention and treatment. Last year, Evvy launched a prospective study in collaboration with IVF clinics, leveraging its vaginal microbiome tests to gather crucial data on how microbial profiles might correlate with IVF success and other fertility outcomes. This real-world research in clinical settings is vital for translating scientific hypotheses into actionable clinical insights.
Jain articulates a powerful aspiration: to empower the industry to move away from the frustrating and often disheartening realm of "unexplained" conditions in women’s health. "Women shouldn’t have to accept unexplained infertility, unexplained recurrence, or unexplained symptoms as answers when what they often mean is that medicine hasn’t caught up to the data yet," she passionately stated. This sentiment resonates deeply with countless women who have faced protracted diagnostic journeys and vague explanations for their health challenges. Evvy aims to provide the missing data to transform these "unexplained" phenomena into scientifically understood and addressable conditions.
A Growing Ecosystem and Future Vision
While Evvy is a prominent player, the landscape of vaginal health innovation is expanding. Other notable companies in this space include Juno Bio, Tiny Health, and Daye, each contributing to a growing ecosystem dedicated to addressing specific aspects of women’s health. This increased activity signals a broader industry recognition of the significant unmet needs and market opportunities within femtech, driven by technological advancements, rising patient advocacy, and a growing understanding of gender-specific health requirements. The investment from Catalio Capital Management, known for its focus on healthcare innovation, further validates the market potential and scientific rigor of companies like Evvy. Catalio’s decision to lead this round suggests a strong belief in Evvy’s long-term vision and its potential to deliver transformative solutions in a historically underserved area.
In the long term, Priyanka Jain envisions Evvy creating nothing less than a "new-age Pap smear." She imagines an "at-home, non-invasive sample that can provide women with more regular, data-rich insights across infections, inflammation, fertility, PCOS, endometriosis, premenopause, HPV progression, and more." This vision represents a paradigm shift from current diagnostic practices, which are often reactive and limited in scope. A comprehensive, regular, at-home test could enable earlier detection, proactive management, and a more holistic understanding of a woman’s health trajectory throughout her life.
Jain concludes with a powerful call to action, emphasizing the urgency and the role of patients themselves in driving progress. "I don’t think we can wait for traditional research methods to catch up," she asserted. "I believe women, as patients, can be part of pushing the industry forward." This statement underscores Evvy’s patient-centric philosophy, recognizing that by empowering individuals with tools and data, they become active participants in accelerating medical discovery and improving healthcare outcomes for all women. The $40 million Series B funding is not just an investment in a company; it is an investment in the future of women’s health, promising a future where "unexplained" gives way to data-driven understanding and personalized care.
About the Author
